Shares of Aimmune rose about 4% in Wednesday morning trading.
The investment includes the purchase of one million shares of Aimmune common stock at $31.97 per share and 525,634 shares of convertible preferred stock, convertible on a one-for-ten shares of common stock basis, for $319.675 per share. The convertible preferred stock has a liquidation preference of $0.0001 per share and does not have any voting rights or stated dividend. In connection with the deal, certain terms of Aimmune's agreements with Nestle have also been extended by one year until Nov. 11, 2021.
After the completion of the transaction, expected to take place on Feb. 7, Nestle's total investments in Aimmune will be equivalent to 19.9% of Aimmune's outstanding common stock and voting power, and 25.6% overall stake in the company's fully-diluted capitalization.
The completion is subject to satisfaction of usual and customary closing conditions.
Price: 30.58, Change: +1.20, Percent Change: +4.10
|Insider Trends: VOXX International Insider Granted S...|
|Market Chatter: Banks Reportedly Balked at Hilcorp's...|
|Sector Update: Tech|
|Research Alert: CFRA Lowers Opinion On General Elect...|
|Analyst Actions: Susquehanna Lowers Qualcomm's Price...|